BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

BioMarin Pharmaceutical is making a smart move in acquiring ALE1 for $275M upfront and potentially $490M in total contingent on development and approval milestones, with no non-ALE1 assets or employees transferring. The sheer size and potential of the hypophosphatasia (HPP) market, demonstrated by AstraZeneca's Strensiq generating ~$1.7B in revenue in 2025, justify the upfront payment and potential milestone payments. While the lack of patient efficacy data is a concern, BioMarin's previous acquisition of Inozyme for ~$270M and subsequent discontinuation of BMN 401 raises concerns about the company's development-stage BD transactions, but the strong sales of VOXZOGO (up 15% Q/Q and raised 2026 guidance) and potential for even higher peak sales mitigate some of these concerns. It is important to watch how the competition with Ascendis Pharma's YUVIWEL (navepegritide) progresses, but overall, BioMarin's financial position and expanding pipeline make it a strong investment opportunity.

BioMarin Pharmaceutical is facing challenges in its quest for commercial diversification, as its $270M investment in Inozyme for BMN 401, a potential first-in-disease enzyme replacement therapy for ENPP1 deficiency, has fallen through due to poor Phase 3 results. This raises questions about the company's ability to offset competition in its core market of achondroplasia, leaving BioMarin heavily reliant on its currently approved therapies for revenue growth and vulnerable to potential setbacks in its pipeline. Moreover, BioMarin is taking on significant debt to fund its acquisitions, with an estimated $3.5B of debt outstanding by end-3Q27, which adds further financial risk to the stock.